GlaxoSmithKline PLC Director/PDMR Shareholding (2966U)
January 16 2017 - 1:08PM
UK Regulatory
TIDMGSK
RNS Number : 2966U
GlaxoSmithKline PLC
16 January 2017
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. Details of PDMR/person closely associated with them
('PCA')
=== ==========================================================================
a) Name Sir Andrew Witty
=== ======================== ================================================
b) Position/status Chief Executive Officer
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 12 January 2017
on Ordinary Shares held in the Company's
2009 Performance Share Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP15.66 230.984
---------- ----------
GBP15.66 4.229
---------- ----------
GBP15.66 1414.139
---------- ----------
GBP15.66 4242.446
---------- ----------
GBP15.66 5799.902
---------- ----------
GBP15.66 6281.971
---------- ----------
GBP15.66 617.137
---------- ----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
18,590.808
GBP15.66
=== ======================== ================================================
e) Date of the transaction 2017-01-12
=== ======================== ================================================
f) Place of the n/a
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ==========================================================================
a) Name Ms E Walmsley
=== ======================== ================================================
b) Position/status CEO Designate
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 12 January 2017
on Ordinary Shares held in the Company's
2009 Performance Share Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP15.66 1470.538
---------- ----------
GBP15.66 1507.800
---------- ----------
GBP15.66 781.531
---------- ----------
GBP15.66 2574.033
---------- ----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
6,333.902
GBP15.66
=== ======================== ================================================
e) Date of the transaction 2017-01-12
=== ======================== ================================================
f) Place of the n/a
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ==========================================================================
a) Name Mr S Dingemans
=== ======================== ================================================
b) Position/status Chief Financial Officer
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 12 January 2017
on Ordinary Shares held in the Company's
2009 Performance Share Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP15.66 2489.181
---------- ----------
GBP15.66 2552.244
---------- ----------
GBP15.66 2764.183
---------- ----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
7,805.608
GBP15.66
=== ======================== ================================================
e) Date of the transaction 2017-01-12
=== ======================== ================================================
f) Place of the n/a
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ==========================================================================
a) Name Mr R G Connor
=== ======================== ================================================
b) Position/status President, Global Manufacturing & Supply
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 12 January 2017
on Ordinary Shares held in the Company's
2009 Performance Share Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP15.66 1144.520
---------- ----------
GBP15.66 1173.521
---------- ----------
GBP15.66 1503.083
---------- ----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
3,821.124
GBP15.66
=== ======================== ================================================
e) Date of the transaction 2017-01-12
=== ======================== ================================================
f) Place of the n/a
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ==========================================================================
a) Name Mr L Debruyne
=== ======================== ================================================
b) Position/status President, Global Vaccines GSK
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 12 January 2017
on Ordinary Shares held in the Company's
2009 Performance Share Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP15.66 327.328
---------- ----------
GBP15.66 300.181
---------- ----------
GBP15.66 378.346
---------- ----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
1,005.855
GBP15.66
=== ======================== ================================================
e) Date of the transaction 2017-01-12
=== ======================== ================================================
f) Place of the n/a
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ==========================================================================
a) Name Mr N Hirons
=== ======================== ================================================
b) Position/status SVP, Global Ethics & Compliance
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 12 January 2017
on Ordinary Shares held in the Company's
2009 Performance Share Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP15.66 568.982
---------- ----------
GBP15.66 620.023
---------- ----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price 1,189.005
GBP15.66
=== ======================== ================================================
e) Date of the transaction 2017-01-12
=== ======================== ================================================
f) Place of the n/a
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ==========================================================================
a) Name Mr S A Hussain
=== ======================== ================================================
b) Position/status President, Global Pharmaceuticals
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 12 January 2017
on Ordinary Shares held in the Company's
2009 Performance Share Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP15.66 2310.737
---------- ----------
GBP15.66 2667.111
---------- ----------
GBP15.66 3006.180
---------- ----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
7,984.028
GBP15.66
=== ======================== ================================================
e) Date of the transaction 2017-01-12
=== ======================== ================================================
f) Place of the n/a
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ==========================================================================
a) Name Mr D S Redfern
=== ======================== ================================================
b) Position/status Chief Strategy Officer
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 12 January 2017
on Ordinary Shares held in the Company's
2009 Performance Share Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP15.66 821.621
---------- ----------
GBP15.66 933.481
---------- ----------
GBP15.66 1089.729
---------- ----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
2,844.831
GBP15.66
=== ======================== ================================================
e) Date of the transaction 2017-01-12
=== ======================== ================================================
f) Place of the n/a
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ==========================================================================
a) Name Ms C Thomas
=== ======================== ================================================
b) Position/status SVP, HR
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 12 January 2017
on Ordinary Shares held in the Company's
2009 Performance Share Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP15.66 1172.271
---------- ----------
GBP15.66 1244.646
---------- ----------
GBP15.66 1371.559
---------- ----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
3,788.476
GBP15.66
=== ======================== ================================================
e) Date of the transaction 2017-01-12
=== ======================== ================================================
f) Place of the n/a
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ==========================================================================
a) Name Mr P C Thomson
=== ======================== ================================================
b) Position/status SVP, Communications & Government Affairs
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 12 January 2017
on Ordinary Shares held in the Company's
2009 Performance Share Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP15.66 559.082
---------- ----------
GBP15.66 720.120
---------- ----------
GBP15.66 789.120
---------- ----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
2,068.322
GBP15.66
=== ======================== ================================================
e) Date of the transaction 2017-01-12
=== ======================== ================================================
f) Place of the n/a
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ==========================================================================
a) Name Dr P J T Vallance
=== ======================== ================================================
b) Position/status President, R&D
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 12 January 2017
on Ordinary Shares held in the Company's
2009 Performance Share Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP15.66 2524.897
---------- ----------
GBP15.66 2588.867
---------- ----------
GBP15.66 3194.057
---------- ----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
8,307.821
GBP15.66
=== ======================== ================================================
e) Date of the transaction 2017-01-12
=== ======================== ================================================
f) Place of the n/a
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ==========================================================================
a) Name Mrs V A Whyte
=== ======================== ================================================
b) Position/status Company Secretary
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 12 January 2017
on Ordinary Shares held in the Company's
2009 Performance Share Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP15.66 168.102
---------- ----------
GBP15.66 159.405
---------- ----------
GBP15.66 150.648
---------- ----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
478.155
GBP15.66
=== ======================== ================================================
e) Date of the transaction 2017-01-12
=== ======================== ================================================
f) Place of the n/a
transaction
=== ======================== ================================================
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHVQLFFDFFBBBD
(END) Dow Jones Newswires
January 16, 2017 13:08 ET (18:08 GMT)
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024
